L100 ESSENTIO SR,L101 ESSENTIO DR,L121 ESSENTIO EL DR,L200 PROPONENT SR,L201 PROPONENT DR,L221 PROPONENT EL DR,L30
Boston Scientific Corp · Decision date Oct 22, 2025
What did the FDA decide?
FDA records N970003/S303 as a supplement to PMA null, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 22, 2025.
FDA approval order statement
to extend the time that solder paste can remain on the stencil before cleaning when building pulse generator printed circuit board assemblies
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 22, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- N970003/S303
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- Decision code
- OK30
- Decision date
- Oct 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N970003/S303 received
Application receipt date recorded by FDA.
N970003/S303 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: N970003/S303
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
